Information about Tiotropium
Tiotropium is a synthetic anticholinergic agent that is used as an inhalant for treatment of acute bronchospasm due to chronic bronchitis or emphysema.
Liver safety of Tiotropium
Tiotropium has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.
Mechanism of action of Tiotropium
Tiotropium (tye" oh troe' pee um) is a synthetic quaternary ammonium anticholinergic which inhibits the muscarinic actions of acetylcholine on autonomic nerve endings, decreasing bronchial smooth muscle contractions and alleviating bronchospasm in patients with chronic obstructive pulmonary disease (COPD). Tiotropium has potent activity against muscarinic acetylcholine receptors found in bronchial smooth muscle. Its quaternary ammonium structure decreases its ability to cross lipid membranes such as the blood brain barrier.
FDA approval information for Tiotropium
Tiotropium was approved for use in the United States in 2004 for use as a respiratory inhalant as maintenance treatment of bronchospasm associated with chronic bronchitis and emphysema.
Brand name for Tiotropium
Tiotropium is available under the brand name Spiriva in capsules of 18 mcg for use in an inhaler (not to be swallowed).
Dosage and administration for Tiotropium
The typical dose in adults is two inhalations of the powder from one capsule once daily. When given by inhaler, tiotropium has minimal systemic absorption.
Side effects of Tiotropium
Side effects of tiotropium are mild, but can include the typical anticholinergic effects of dryness of the mouth and eyes, visual blurring, constipation, tachycardia and palpitations, anxiety and restlessness. Tiotropium use can cause paradoxical bronchospasm. Anticholinergic agents can precipitate acute narrow angle glaucoma and acute urinary retention.